Please login to the form below
Kesimpta
This page shows the latest Kesimpta news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients
Kesimpta is the first subcutaneous B-cell therapy that can be self-administered at home for people with RRMS. ... The overall fatal outcome (0.8%) and hospitalisation rates (9.4%) due to COVID-19 in Kesimpta-treated patients were lower than the rates
Latest news
-
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
Rejuvenation of our portfolio continues, from our key brands which include Kesimpta, Leqvio, Zolgensma and the oncology portfolio,” said Novartis CEO Vas Narasimhan.
-
Novartis sees demand returning to pre-COVID-19 levels in Q2 results
growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab). ... Both Kesimpta and Ocrevus selectively target the immune system’s CD20-positive B cells that damage nerve tissue and
-
Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
Kesimpta was approved in the EU for the treatment of RMS in adults with active disease at the end of March. ... Kesimpta also met the key secondary endpoints, which included delaying time to confirmed disability progression, in the head-to-head study.
-
Novartis gains EU approval for relapsing MS drug Kesimpta
Kesimpta also met the key secondary endpoints, which included delaying time to confirmed disability progression, in the head-to-head study. ... According to Genmab, Kesimpta is the first B-cell therapy that can be self-administered at home using
More from news
Approximately 4 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Reaching patients and HCPs during the pandemic
Self-administered injectables, such as Novo Nordisk’s recently approved therapy for adult growth hormone deficiency (GHD), Sogroya (somapacitan), and Novartis’ much-hyped MS treatment, Kesimpta (ofatumumab), will be tested in
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Recognising HIV Vaccine Awareness Day
- Scientists discover new approach to treat brain tumours
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Part 1 of the Medscape video interview series
- NHS England appoints Chris Hopson as its new chief strategy officer
- Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month
- Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children
- AbbVie submits Parkinson’s disease therapy to FDA
- When is an agency not an agency?
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Kim Lemon appointed head of Liberation Unlimited
- Perrigo expands consumer health with €3.6bn Omega purchase
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- We’ll need more than a spoonful of sugar to counter vaccine hesitancy
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- When is an agency not an agency?
- The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
